Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
This page provides a historical news archive for Cerevel Therapeutics Holdings, Inc. (formerly Nasdaq: CERE), a neuroscience-focused biopharmaceutical company that became part of AbbVie following the completion of an acquisition announced by AbbVie on August 1, 2024. Before the transaction, Cerevel regularly issued updates on its clinical pipeline, corporate strategy and capital raising activities.
News items for Cerevel include detailed announcements on its key investigational therapies such as emraclidine, tavapadon, darigabat, CVL-871 and CVL-354. These releases cover topics like Phase 2 and Phase 3 trial designs, topline clinical results, regulatory designations and development plans in schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, Parkinson’s disease, mood disorders and related neuroscience indications. For example, Cerevel announced positive topline results from the pivotal Phase 3 TEMPO-3 adjunctive trial of tavapadon in people living with Parkinson’s disease.
Investors and researchers can also review historical corporate and financial communications, including quarterly financial results, business updates, investor webcasts, and the October 2023 public offering of common stock that Cerevel stated would support operations and planned data readouts. In addition, the archive reflects transaction-related news, such as the December 6, 2023 joint announcement by AbbVie and Cerevel of a definitive acquisition agreement, and subsequent commentary from law firms examining the terms of the merger.
Although CERE shares are no longer expected to trade following the closing of the AbbVie acquisition, this news history remains useful for understanding how Cerevel’s neuroscience programs evolved, how management communicated clinical milestones, and how the acquisition rationale was framed by AbbVie. Users interested in ongoing development of these assets should consult AbbVie’s current disclosures, while using this page as a record of Cerevel’s standalone public-company era.
Cerevel Therapeutics (NASDAQ:CERE) announced participation in three virtual investor conferences in November 2020. The events include:
- Guggenheim Healthcare Talks on November 16, focusing on neuro/immunology.
- Stifel 2020 Virtual Healthcare Conference on November 17, featuring a fireside chat at 10:00 a.m. EST.
- Jefferies Virtual London Healthcare Conference on November 18-19, with a chat at 10:50 a.m. EST on November 18.
Live webcasts will be available on the company's investor relations page.
Cerevel Therapeutics has initiated the first patient dosing in three Phase 3 trials for tavapadon, a treatment for Parkinson's disease. These 27-week trials, involving 1,200 patients, aim to assess the efficacy and tolerability of the drug as both a monotherapy and adjunctive therapy. Preliminary data readouts are expected in the first half of 2023. Tavapadon has shown promise in earlier trials, with a focus on receptor selectivity to reduce side effects commonly associated with similar therapies. Cerevel aims to provide a cornerstone treatment for patients at all disease stages.
Cerevel Therapeutics completed its business combination with Arya Sciences Acquisition Corp II on October 27, 2020, resulting in the formation of Cerevel Therapeutics Holdings, Inc. Common stock and warrants began trading on Nasdaq under symbols CERE and CEREW. The transaction generated $440 million in net proceeds, combining funds from Arya II's trust account and a PIPE financing. The management team, led by CEO Tony Coles, aims to address neuroscience diseases, leveraging its extensive pipeline for conditions like schizophrenia and Parkinson's disease.